Iron overload in myelodysplastic syndromes: A Canadian consensus guideline

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1338-1353

  Wells, Richard A ^a   Leber, Brian ^b   Buckstein, Rena ^a   Lipton, Jeffrey H ^c   Hasegawa, Wanda ^d   Grewal, Kuljit ^e   Yee, Karen ^c   Olney, Harold J ^f   Larratt, Loree ^g   Vickars, Linda ^h   Tinmouth, Alan ⁱ  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e Health Sciences Centre St John's   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Deferasirox; Deferoxamine; Deferriprone; Desferal; Exjade; Ferriprox; Guideline; Iron chelation; Iron overload; Myelodysplastic syndromes; Prognosis; Secondary hemosiderosis; Transfusion

Indexed keywords

ASCORBIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2;

ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANADA; CATARACT; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HEART DISEASE; HUMAN; HYPERPARATHYROIDISM; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; KIDNEY FAILURE; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; OTOTOXICITY; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; SEIZURE; SIDE EFFECT; THALASSEMIA; TRANSFUSION; YERSINIOSIS;

EID: 43049167385     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.02.021     Document Type: Review

References (82)

1. R. Buckstein K. Jang A. Chesney Estimating the prevalence and a pre-test likelihood of myelodysplasia: a restrospective review of bone marrow histopathology in 322 cases of unexplained cytopenia(s) in a teaching hospital Leuk Res 31 Suppl. 2007 S23
2. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;103(4):1070–74.
3. N. Gatterman Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload Leuk Res 31 Suppl. 3 2007 S10 S15
4. Carrington, P on behalf of the British Committee for Standards in Haematology. Evidence levels and grades of recommendation. Appendix 7. Procedures for Guidelines Commissioned by the BCSH; July 2006. Accessed online at: www.bcshguidelines.com/process1.asp#appendix7 .
5. L.R. Weintraub M.E. Conrad W.H. Crosby Regulation of the intestinal absorption of iron by the rate of erythropoiesis Br J Haematol 11 1965 432 438
6. M.G. Zurlo P. De Stefano C. Borgna-Pignatti Survival and causes of death in thalassaemia major Lancet 2 1989 27 30
7. N.F. Oliveri D.G. Nathan J.M. MacMillan Survival in medically treated patients with homozygous beta-thalassemia N Engl J Med 331 1994 574 578
8. N.C. Andrews Iron homeostasis: insights from genetics and animal models Nat Rev Genet 1 2000 208 217
9. M.W. Hentze M.U. Muckenthaler N.C. Andrews Balancing acts: molecular control of mammalian iron metabolism Cell 117 2004 285 297
10. M. Shayeghi G.O. Latunde-Dada J.S. Oakhill Identification of an intestinal heme transporter Cell 122 2005 789 801
11. A. Pietrangelo Genetic hemaochromatosis: a new look at an old disease N Engl J Med 350 2004 2383 2397
12. E. Nemeth M.S. Tuttle J. Powelson Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization Science 306 2004 2090 2093
13. J.L. Babitt F.W. Huang D.M. Wrighting Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression Nat Genet 38 2006 531 539
14. G. Nicholas C. Chauvet L. Viatte The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation J Clin Invest 110 2002 1037 1044
15. W. Breuer A. Ronson I.N. Slotki The assessment of serum non-transferrin bound iron in chelation therapy and iron supplementation Blood 95 2000 2975 2982
16. W. Breuer M.J. Ermers P. Pootrakul Desferrioxamine-chelatable iron, a component of serum non-transferrin bound iron used for assessing chelation therapy Blood 97 2001 792 798
17. B.P. Esposito W. Breuer P. Sirankapracha Labile plasma iron in iron overload: redox activity and susceptibility to chelation Blood 102 2003 2670 2677
18. W.C. Wang N. Ahmed M. Hanna Non-transferrin-bound iron in long-term transfusion in children with congenital anemias J Pediatr 108 1986 552 557
19. P. Pootrakul W. Breuer M. Sametband Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded beta thalassemia/hemoglobin E patients treated with an oral chelator Blood 104 2004 1504 1510
20. P.D. Jensen F.T. Jensen T. Christensen J.L. Nielsen J. Ellegaard Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias Blood 101 2003 91 96
21. P.D. Jensen F.T. Jensen T. Christensen Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy Blood 101 2003 4632 4639
22. C. Le Lan O. Loreal T. Choen Redox active plasma iron in C282Y/C282Y hemochromatosis Blood 105 2005 4527 4531
23. A.I. Schafer R.G. Cheron R. Dluhy Clinical consequences of acquired transfusional iron overload in adults N Engl J Med 304 1981 319 324
24. M. Jaeger C. Aul D. Sohngen U. Germing W. Schneider Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes Beitr Infusionsther 30 1992 464 468
25. M. Cazzola G. Barosi P.G. Gobbi R. Invernizzi A. Riccardi E. Ascari Natural history of idiopathic refractory sideroblastic anemia Blood 72 2 1988 305 312
26. J. Chacko D.J. Pennell M.A. Tanner Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions Br J Haematol 138 5 2007 Sep 587 593
27. T.E. Delea M. Hagiwara P.D. Phatak Retrospective, nested, case-control study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders Blood 108 2006 Abstract 968
28. C. Niederau R. Fisher A. Sonnenberg Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis N Engl J Med 313 1985 1256 1262
29. C. Niederau R. Fischer A. Purschel Long-term survival in patients with genetic hemaochromatosis Gastroenterology 110 1996 1107 1119
30. L. Malcovati M.G. Porta C. Pascutto Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 2005 7594 7603
31. M. Takatoku T. Uchiyama S. Okamoto The Japanese National Research Group on idiopathic bone marrow failure syndromes Eur J Haematol 78 6 2007 487 494 [Epub 2007, March 28]
32. M.J. Kersten R. Lange M.E. Smeets Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial Ann Hematol 73 1996 247 252
33. J.I. Henter J. Karlén Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia Blood 109 12 2007 5157 5159
34. A.R. Cohen R. Galanello A. Piga V. De Sanctis F. Tricta Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 102 5 2003 1583 1587 [Epub ahead of print: May 22, 2003]
35. A. Ceci P. Baiardi M. Felisi The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients Br J Haematol 118 1 2002 330 336
36. A.R. Cohen R. Galanello A. Piga A. Dipalma C. Vullo F. Tricta Safety profile of the oral iron chelator deferiprone: a multicentre study Br J Haematol 108 2 2000 305 312
37. A. Castriota-Scandberg M. Sacco Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (dereriprone) Br J Haematol 96 2 1997 254 255
38. N. Gattermannn M. Cazzola P. Greenberg The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload Leuk Res 29 Suppl. 1 2005 S67
39. P. Brissot P. Deugnier H. Cianciulli Correlation between dose-dependent reductions in serum transaminase (ALT) and serum ferritin levels during long-term chelation therapy with deferasirox Blood 108 2006 [Abstract 3817]
40. P. Greenberg G. Dine A. Ganser Deferasirox demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia Blood 106 2005 [Abstract 2694]
41. P.D. Jensen N. Olsen J.P. Bagger Cardiac function during iron chelation therapy in adult non-thalassemic patients with transfusional iron overload Eur J Hematol 59 1997 221 230
42. H.A. Leitch T.A. Goodman K.K. Wong L.M. Vickars Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy Blood 108 2006 [Abstract 249]
43. P. Greenberg C. Cox M.M. Lebeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 6 1997 2079 2088
44. C. Rose S. Brechnignac D. Vassilief Positive impact of iron chelation therapy (CT) in regularly transfused MDS patients. A prospective analysis by the GFM Blood 110 2007 [Abstract 249]
45. P.D. Jensen L. Heickendorff B. Pedersen The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload Br J Haematol 94 1996 288 299
46. P. Armand H.T. Kim C.S. Cutler Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation Blood 109 10 2007 4586 4588 [Epub Jan 18, 2007]
47. P.D. Jensen F.T. Jansen T. Christensen J. Ellegaard Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassemic patients Br J Hematol 89 1995 880 889
48. Y. Gandon D. Olivie D. Guyader Non-invasive assessment of iron stores by MRI Lancet 363 2004 341 342
49. C. Rose P. Vandevenne E. Bourgeois N. Cambier O. Ernst Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients Eur J Haematol 77 2006 145 149
50. L.J. Anderson S. Holden B. Davis Cardivascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload Eur Heart J 22 2001 2171 2179
51. T.G. St. Pierre P.R. Clark W. Chua-Anusom Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance Blood 105 2005 855 861
52. D.J. Pennell T2* magnetic resonance and myocardial iron in thalassemia Ann NY Acad Sci 1054 2005 373 378
53. M.A. Westwood B. Wonke A.M. Maceira Left ventricular diastolic function compared with t2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major J Magn Reson Imaging 22 2005 229 233
54. L.J. Anderson M.A. Westwood S. Holden Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance Br J Haematol 127 2004 348 355
55. D. Bowen D. Culligan S. Jowitt UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 2 2003 187 200
56. E.P. Alessandrino S. Amadori G. Barosi Italian Society of Hematology. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology Haematoligica 87 12 2002 1286 1306
57. NCCN Clinical practice Guidelines in Oncology: Myelodysplastic Syndromes V.1 2007. http://www.nccn.org/professionals/physician_glsPDF/mds.pdf .
58. N. Gattermann J. Porter L.F. Lopes J. Seymour Consensus statement on iron overload in myelodysplastic syndromes Hematol Oncol Clin North Am 19 Suppl. 1 2005 18 25
59. K. Shinjo A. Takeshita K. Naito Successful treatment using iron depletion phlebotomy combined with recombinant erythropoietin after allogeneic bone marrow transplantation for myelodysplastic syndrome complicated by secondary hemochromatosis [Japanese] Rinsho Ketsueki: Jpn J Clin Hematol 42 7 2001 571 574
60. B. Agroyannis D. Koutsicos H. Tzanatou-Exarchou Combined recombinant human erythropoietin-blood letting strategy for treating anemia and iron overload in hemodialysis patients [see comment] Int J Artificial Organs 14 7 1991 403 406
61. K. Onoyama S. Nakamura M. Yamamoto Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: confirmation by follow-up liver biopsy Nephron 56 3 1990 325 328
62. F.A. Gonzalez B. Arrizabalaga A. Villegas Grupo Espanol de Eritropatologia Espanola de Hematologia y Hemoterapia [Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes][see comment] Medicina Clinica 124 17 2005 645 647 [Spanish]
63. C. Borgna-Pignatti M. Franchini G. Gandini Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload Haematologica 83 9 1998 788 790
64. M. Kobayashi K. Yano S. Fujisawa Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis [Japanese] Rinsho Ketsueki: Jpn J Clin Hematol 37 4 1996 303 310
65. D.R. Ambruso B.S. Mahony J.H. Githens E.D. Rhoades Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome Am J Pediatr Hematol Oncol 4 2 1982 115 123
66. Mosby's Drug Consult 2006. Elsevier Inc. Accessed online at: www.mosbysdrugconsult.com/DrugConsult/ .
67. L.A. Styles E.P. Vichinsky Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine J Pediatr Hematol Oncol 18 1 1996 42 45
68. R.M. Robins-Browne J.K. Prpic S.J. Stuart iron. Yersiniae A study in host-parasite relationships Contrib Microbiol Immunol 9 1987 254 258
69. J.R. Boelaert G.F. van Roost P.L. Vergauwe J.J. Verbanck C. de Vroey M.F. Segaert The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature Clin Nephrol 29 5 1988 261 266
70. R.T. O’Brien Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major Ann NY Acad Sci 232 1974 221 225
71. V. Herbert S. Shaw E. Jayatilleke T. Stopler-Kasdan Most free-radical injury is iron-related: it is promoted by iron, hemin, heleferritin, and vitamin C, and inhibited by desferoxamine and apoferritin Stem Cells 12 3 1994 May 289 303
72. G.J. Kontoghiorghes M.A. Aldouri L. Sheppard A.V. Hoffbrand 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload Lancet 1 8545 1987 1294 1295
73. G.J. Kontoghiorghes M.A. Aldouri A.V. Hoffbrand Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one Br Med J Clin Res Ed 295 6612 1987 1509 1512
74. E. Vichinsky O. Onyekwere J. Porter Deferasirox in sickle cell investigators. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease Br J Haematol 136 3 2007 501 508
75. R. Galanello A. Piga G.L. Forni Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major Haematologica 91 10 2006 1343 1351
76. A. Piga R. Galanello G.L. Forni Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload Haematologica 91 2006 873 880
77. M.D. Cappellini A. Cohen A. Piga A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia Blood 107 2006 3455 3462
78. H. Glickstein R.B. El M. Shvartsman Z.I. Cabantchik Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells Blood 106 2005 3242 3250
79. H. Glickstein R.B. El G. Link Action of chelators in iron-overloaded cardiac cells: accessibility to intracellular labile iron and functional consequences Blood 108 2006 3195 3203
80. C. Ferte O. Ernst M.P. Beyne-Rauzy Clinical relevance of cardiac iron overload estimated by MRI T2* in regularly transfused low-risk MDS Blood 108 2006 [Abstract 2666]
81. P.D. Jensen L. Heickandorff H.M. Helweg-Larsen Serum procollagen III peptide concentration in iron overload Eur J Hematol 57 1996 157 164
82. T. Tanno N.V. Bhanu P.A. Oneal High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin Nat Med. 13 9 2007 1096 1101